Last reviewed · How we verify
NCT06768658
A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)
Phase 1 trial testing TAK-951 in Nausea and Vomitting in 1 participant. Terminated before completion.
9 January 2023
Quick facts
| Lead sponsor | Takeda |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 2 March 2022 |
| Primary completion | 9 January 2023 |
| Estimated completion | 9 January 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- TAK-951 — full drug profile →
- TAK-951 Placebo
Conditions studied
- Nausea and Vomitting — all drugs for Nausea and Vomitting →
Sponsor
Takeda — full company profile →
Who can join
Adults 18 to 50, any sex, with Nausea and Vomitting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS). The main aims of this study are as follows: * To check for side effects from treatment with TAK-951. * To learn how much TAK-951 participants can receive without getting side effects from it. * To check how much TAK-951 stays in the blood over time to work out the best dose. * The dose of TAK-951 will be checked to see how much stays in their blood over time. * To see if it is possible to give treatment at home. Participants will be given TAK-951 injected just under the skin (subcutaneous or SC).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06768658
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TAK-951
Trials testing the same drug.
- NCT06610279 — A Study of TAK-951 in Healthy Adults · Phase 1 · terminated
- NCT04557189 — A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery · Phase 2 · completed
- NCT04486950 — A Study of TAK-951 in Healthy Adults · Phase 1 · completed
- NCT05567393 — A Study of TAK-951 in Healthy Adults · Phase 1 · completed
Other Takeda trials
Trials by the same sponsor.
- NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
- NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
- NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
- NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
- NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06768658 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Takeda
- Last refreshed: 2 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06768658.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing